Given the similarity between AML and CML in terms of oncogene-driven mechanisms, it is likely that the overexpression of SNAI2 in AML plays a similar role in promoting resistance and cell proliferation to standard AML therapies. The gene discussed is SNAI2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.